Is Sarepta Therapeutics Worthy of Redemption?

Is Sarepta Therapeutics Worthy of Redemption?

Source: 
Motley Fool
snippet: 

Sarepta Therapeutics (NASDAQ:SRPT) is a medical research and drug development company based in Cambridge, Mass. Founded in 1980, Sarepta currently has three drugs approved for a condition known as Duchenne muscular dystrophy, or DMD. Another potential treatment for the condition, SRP-9001, is undergoing phase 2 trials, and while complete biomarker data has not yet been released, partial results that came out in January were not well received. While the primary endpoint was achieved, statistical significance was lacking.